Characterization of α1‐adrenoceptor subtypes in tension response of human prostate to electrical field stimulation
暂无分享,去创建一个
[1] M. Wyllie,et al. Pharmacological properties of the cloned α1A/D‐adrenoceptor subtype are consistent with the α1A‐adrenoceptor characterized in rat cerebral cortex and vas deferens , 1994 .
[2] T. Branchek,et al. Selective irreversible binding of chloroethylclonidine at alpha 1- and alpha 2-adrenoceptor subtypes. , 1993, Molecular pharmacology.
[3] G. Strada,et al. Characterization of α1-adrenoceptor subtypes in prostate and prostatic urethra of rat, rabbit, dog and man , 1993 .
[4] M. Caron,et al. Identification, quantification, and localization of mRNA for three distinct alpha 1 adrenergic receptor subtypes in human prostate. , 1993, The Journal of urology.
[5] J. Docherty,et al. Investigation of the subtypes of alpha 1-adrenoceptor mediating contractions of rat aorta, vas deferens and spleen. , 1993, British journal of pharmacology.
[6] H. Lepor,et al. Alpha 1 adrenoceptor subtypes in the human prostate. , 1993, The Journal of urology.
[7] J. Lomasney,et al. Pharmacologic characterization of cloned alpha 1-adrenoceptor subtypes: selective antagonists suggest the existence of a fourth subtype. , 1992, European journal of pharmacology.
[8] M. Macías-Silva,et al. Species heterogeneity of hepatic ?1-adrenoceptors: ?1A-, ?1B- and ?1C-subtypes , 1992 .
[9] T. Philipp,et al. α‐ and β‐Adrenoceptors in Hypertension: Molecular Biology and Pharmacological Studies , 1992 .
[10] M. Caron,et al. The alpha 1C-adrenergic receptor: characterization of signal transduction pathways and mammalian tissue heterogeneity. , 1991, Molecular pharmacology.
[11] H. Bensadoun,et al. Alfuzosin for treatment of benign prostatic hypertrophy , 1991, The Lancet.
[12] M. Caron,et al. Molecular cloning and expression of the cDNA for the alpha 1A-adrenergic receptor. The gene for which is located on human chromosome 5. , 1991, The Journal of biological chemistry.
[13] K. Minneman,et al. Subtypes of α1adrenoceptors in rat blood vessels , 1990 .
[14] G. Burnstock,et al. Autoradiographic analysis of alpha-adrenoceptors and muscarinic cholinergic receptors in the hyperplastic human prostate. , 1989, The Journal of urology.
[15] G. Gross,et al. Subclassification of α1‐adrenoceptor recognition sites by urapidil derivatives and other selective antagonists , 1989, British journal of pharmacology.
[16] M. Caron,et al. Molecular cloning and expression of the cDNA for the hamster alpha 1-adrenergic receptor. , 1988, Proceedings of the National Academy of Sciences of the United States of America.
[17] G. Gross,et al. 5-Methyl-urapidil discriminates between subtypes of the α1-adrenoceptor , 1988 .
[18] K. Minneman. Alpha 1-adrenergic receptor subtypes, inositol phosphates, and sources of cell Ca2+. , 1988, Pharmacological reviews.
[19] P. Abel,et al. Comparison of alpha 1-adrenergic receptor subtypes distinguished by chlorethylclonidine and WB 4101. , 1988, Molecular pharmacology.
[20] T. Kenakin,et al. Classification of phenoxybenzamine/prazosin-resistant contractions of rat spleen to norepinephrine by Schild analysis: similarities and differences to postsynaptic alpha-2 adrenoceptors. , 1988, The Journal of pharmacology and experimental therapeutics.
[21] R. Kirby,et al. Prazosin in the treatment of prostatic obstruction. A placebo-controlled study. , 1987, British journal of urology.
[22] J. Kumazawa,et al. Pharmacological characteristics of smooth muscle in benign prostatic hyperplasia and normal prostatic tissue. , 1987, The Journal of urology.
[23] S. Yamada,et al. Alpha-1 adrenoceptors in human prostate: characterization and alteration in benign prostatic hypertrophy. , 1987, The Journal of pharmacology and experimental therapeutics.
[24] P. Abel,et al. α1Adrenoceptor subtypes linked to different mechanisms for increasing intracellular Ca2+ in smooth muscle , 1987, Nature.
[25] M. Caine. Clinical experience with alpha-adrenoceptor antagonists in benign prostatic hypertrophy. , 1986, Federation proceedings.
[26] K. Andersson,et al. Alpha-adrenoceptors and muscarinic receptors in the isolated human prostate. , 1985, The Journal of urology.
[27] D. Triggle,et al. Calcium channel antagonists: pharmacological considerations. , 1985, British journal of clinical pharmacology.
[28] J. Hieble,et al. In vitro characterization of the alpha-adrenoceptors in human prostate. , 1985, European journal of pharmacology.
[29] S. Meretyk,et al. A placebo-controlled double-blind study of the effect of phenoxybenzamine in benign prostatic obstruction. , 1978, British journal of urology.
[30] D. Mackay. How should values of pA2 and affinity constants for pharmacological competitive antagonists be estimated? , 1978, The Journal of pharmacy and pharmacology.
[31] H. Schild,et al. SOME QUANTITATIVE USES OF DRUG ANTAGONISTS , 1997, British journal of pharmacology and chemotherapy.